{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    40,
    41,
    42,
    43,
    44,
    46,
    48,
    49,
    50,
    51,
    52,
    69,
    70,
    71,
    90
  ],
  "modelUsed": "gemini-3-flash-preview",
  "data": {
    "timeAnchors": [
      {
        "id": "anchor_llm_1",
        "definition": "The day of the first vaccination (Vaccination 1)",
        "anchorType": "Day1",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Visit Number 1, Visit Description Vaccination 1, Visit Window (Days) Day 1"
      },
      {
        "id": "anchor_1",
        "definition": "Informed consent obtained",
        "anchorType": "InformedConsent",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "informed consent"
      },
      {
        "id": "anchor_2",
        "definition": "procedure",
        "anchorType": "Custom",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "procedure"
      }
    ],
    "repetitions": [
      {
        "id": "rep_daily_1",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "od"
      },
      {
        "id": "rep_daily_2",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "OD"
      },
      {
        "id": "rep_window_1",
        "type": "Continuous",
        "sourceText": "42 Days After"
      },
      {
        "id": "rep_window_3",
        "type": "Continuous",
        "sourceText": "196 Days After"
      },
      {
        "id": "rep_window_6",
        "type": "Continuous",
        "sourceText": "7 days after"
      },
      {
        "id": "rep_window_7",
        "type": "Continuous",
        "sourceText": "10 days after"
      },
      {
        "id": "rep_window_9",
        "type": "Continuous",
        "sourceText": "42 days after"
      },
      {
        "id": "rep_window_14",
        "type": "Continuous",
        "sourceText": "42 Days \nAfter"
      },
      {
        "id": "rep_window_16",
        "type": "Continuous",
        "sourceText": "196 Days \nAfter"
      },
      {
        "id": "rep_window_20",
        "type": "Continuous",
        "sourceText": "28 days after"
      },
      {
        "id": "rep_window_22",
        "type": "Continuous",
        "sourceText": "42 Days\nAfter"
      },
      {
        "id": "rep_window_46",
        "type": "Continuous",
        "sourceText": "28 days before"
      },
      {
        "id": "rep_window_47",
        "type": "Continuous",
        "sourceText": "60 days before"
      },
      {
        "id": "rep_window_48",
        "type": "Continuous",
        "sourceText": "48 hours before"
      },
      {
        "id": "rep_llm_1",
        "type": "Cycle",
        "startOffset": "P0D",
        "endOffset": "P42D",
        "interval": "P28D",
        "minObservations": 2,
        "exitCondition": "Completion of Vaccination 2",
        "sourceText": "Cohort 1: Visit 2 (Vaccination 2 – 28 to 42 Days After Visit 1)"
      },
      {
        "id": "rep_llm_2",
        "type": "Continuous",
        "startOffset": "P168D",
        "endOffset": "P196D",
        "interval": "P1D",
        "minObservations": 1,
        "exitCondition": "Completion of 6-Month Safety Collection",
        "sourceText": "6-Month Safety Collection [Telephone Contact] – 168 to 196 Days After Vaccination 1"
      },
      {
        "id": "rep_llm_3",
        "type": "Daily",
        "startOffset": "P0D",
        "endOffset": "null",
        "interval": "P1D",
        "minObservations": 7,
        "exitCondition": "End of diary reporting period",
        "sourceText": "7.2.1. Subject Electronic Diary"
      }
    ],
    "samplingConstraints": [],
    "traversalConstraints": [
      {
        "id": "traversal_1",
        "requiredSequence": [
          "SCREENING",
          "VACCINATION_1",
          "VACCINATION_2_OR_FOLLOW_UP",
          "IMMUNOGENICITY_FOLLOW_UP",
          "END_OF_STUDY_TELEPHONE_CONTACT"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "Day 1",
          "Screening",
          "End of Study",
          "Visit 2 (Day 28-42)",
          "Visit 1 (Day 1)",
          "Visit 4 (6-Month Telephone Contact)"
        ],
        "sourceText": "[{'condition': 'Subject is in Cohort 1 (Age >= 60)', 'path': ['Visit 1 (Vaccination 1)', 'Visit 2 (Vaccination 2)', 'Visit 3 (Blood Draw)', 'Visit 4 (6-Month Follow-up)']}, {'condition': 'Subject is in Cohort 2 or 3 (Age 18-59)', 'path': ['Visit 1 (Vaccination 1)', 'Visit 2 (Blood Draw)', 'Visit 4 (6-Month Follow-up)']}]"
      }
    ],
    "executionTypes": [
      {
        "activityId": "Blood Draw",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Pe",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 3"
      },
      {
        "activityId": "Ae",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Concomitant Medications",
        "executionType": "Single",
        "rationale": "SINGLE signals: 3"
      },
      {
        "activityId": "Diary",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Physical Examination",
        "executionType": "Single",
        "rationale": "The protocol specifies physical examination based on medical history at screening/baseline to determine inclusion."
      },
      {
        "activityId": "Clinical Assessment",
        "executionType": "Single",
        "rationale": "The Schedule of Activities and amendment history indicate clinical assessments are performed at study visits."
      },
      {
        "activityId": "Safety Monitoring (SAEs)",
        "executionType": "Single",
        "rationale": "Section 8 requires reporting of SAEs occurring within a 30-day window after vaccination."
      },
      {
        "activityId": "Temperature Monitoring",
        "executionType": "Single",
        "rationale": "Table 7 and Section 7.2 refer to temperature ranges and monitoring for a period following vaccination."
      },
      {
        "activityId": "Immunogenicity Bridging Analysis",
        "executionType": "Single",
        "rationale": "This is a specific data analysis activity performed once to compare cohorts."
      }
    ],
    "footnoteConditions": [
      {
        "id": "fn_cond_1",
        "conditionType": "procedure_timepoints",
        "text": "a. Control group from enrollment and vaccination with 13vPnC at Visit 1 until vaccination with PPSV23 at Visit 2.",
        "footnoteId": "fn_1",
        "structuredCondition": "interval.between(Visit_1, Visit_2)",
        "appliesToActivityIds": [
          "Control group monitoring",
          "13vPnC vaccination"
        ],
        "sourceText": "a. Control group from enrollment and vaccination with 13vPnC at Visit 1 until vaccination with PPSV2"
      },
      {
        "id": "fn_cond_2",
        "conditionType": "timing_after",
        "text": "b. Control group after vaccination with PPSV23 at Visit 2.",
        "footnoteId": "fn_2",
        "structuredCondition": "timing.after(Visit_2)",
        "appliesToActivityIds": [
          "Control group monitoring"
        ],
        "sourceText": "b. Control group after vaccination with PPSV23 at Visit 2."
      },
      {
        "id": "fn_cond_3",
        "conditionType": "timing_after",
        "text": "c. SAEs and newly diagnosed chronic medical conditions (NDCMCs) will be collected through 6 months after Visit 1.",
        "footnoteId": "fn_3",
        "structuredCondition": "timing.after(Visit_1, P6M)",
        "appliesToActivityIds": [
          "SAE collection",
          "NDCMC collection"
        ],
        "sourceText": "c. SAEs and newly diagnosed chronic medical conditions (NDCMCs) will be collected through 6 months a"
      }
    ],
    "endpointAlgorithms": [
      {
        "id": "ep_1",
        "name": "Primary Safety: Local Reactions",
        "endpointType": "Primary",
        "inputs": [
          "redness",
          "swelling",
          "pain at injection site"
        ],
        "timeWindow": {
          "reference": "vaccination",
          "duration": "P10D"
        },
        "algorithm": "count(reported_prompted_local_reactions)",
        "successCriteria": "Descriptive safety profile",
        "sourceText": "Reported prompted local reactions (redness, swelling, and pain at the injection site) within 10 days after vaccination."
      },
      {
        "id": "ep_2",
        "name": "Primary Safety: Systemic Events",
        "endpointType": "Primary",
        "inputs": [
          "fever",
          "headache",
          "fatigue",
          "muscle pain",
          "joint pain"
        ],
        "timeWindow": {
          "reference": "vaccination",
          "duration": "P7D"
        },
        "algorithm": "count(reported_prompted_systemic_events)",
        "successCriteria": "Descriptive safety profile",
        "sourceText": "Reported prompted systemic events (fever, headache, fatigue, muscle pain, and joint pain) within 7 days after vaccination."
      },
      {
        "id": "ep_3",
        "name": "Primary Immunogenicity: OPA Titers (Cohort 1)",
        "endpointType": "Primary",
        "inputs": [
          "serotype-specific OPA titers"
        ],
        "timeWindow": {
          "reference": "vaccination",
          "duration": "P1M"
        },
        "algorithm": "Geometric Mean Titers (GMTs) comparison (20vPnC vs 13vPnC/PPSV23)",
        "successCriteria": "Noninferiority to 13vPnC (13 serotypes) and PPSV23 (7 additional serotypes)",
        "sourceText": "Serotype-specific opsonophagocytic activity (OPA) titers 1 month after vaccination."
      },
      {
        "id": "ep_4",
        "name": "Secondary Immunogenicity: OPA Titers (Cohort 2 & 3)",
        "endpointType": "Secondary",
        "inputs": [
          "serotype-specific OPA titers"
        ],
        "timeWindow": {
          "reference": "vaccination",
          "duration": "P1M"
        },
        "algorithm": "Geometric Mean Titers (GMTs) comparison (Cohort 2 or 3 vs Cohort 1 60-64 years)",
        "successCriteria": "Noninferiority to immune responses induced by 20vPnC in adults 60 through 64 years of age",
        "sourceText": "Serotype-specific OPA titers 1 month after vaccination."
      },
      {
        "id": "ep_5",
        "name": "Secondary Immunogenicity: Fold Rise",
        "endpointType": "Secondary",
        "inputs": [
          "OPA titer baseline",
          "OPA titer 1 month"
        ],
        "timeWindow": {
          "reference": "vaccination",
          "duration": "P1M"
        },
        "algorithm": "OPA_titer_post_vaccination / OPA_titer_pre_vaccination",
        "successCriteria": "Descriptive immune response",
        "sourceText": "Fold rise in serotype-specific OPA titers from before to 1 month after vaccination."
      }
    ],
    "derivedVariables": [
      {
        "id": "dv_1",
        "name": "Serotype-specific OPA GMTs",
        "variableType": "Custom",
        "sourceVariables": [
          "OPA titers"
        ],
        "derivationRule": "exp(mean(ln(OPA titers)))",
        "baselineDefinition": "Sera collected before study vaccination (Visit 1)",
        "baselineVisit": "Visit 1",
        "analysisWindow": "1 month after each vaccination",
        "imputationRule": "Missing assay results will not be replaced or imputed. OPA titers below LLOQ handled per SAP.",
        "unit": "Titer"
      },
      {
        "id": "dv_2",
        "name": "OPA GMR (20vPnC/saline to 13vPnC/PPSV23)",
        "variableType": "Custom",
        "sourceVariables": [
          "OPA titers"
        ],
        "derivationRule": "exp(mean(ln(20vPnC group)) - mean(ln(13vPnC/PPSV23 group)))",
        "baselineDefinition": "N/A",
        "baselineVisit": "N/A",
        "analysisWindow": "Visit 2 (13 matched serotypes) or Visit 3 (7 additional serotypes)",
        "imputationRule": "Missing assay results will not be replaced or imputed.",
        "unit": "Ratio"
      },
      {
        "id": "dv_3",
        "name": "OPA GMFR",
        "variableType": "PercentChange",
        "sourceVariables": [
          "OPA titers"
        ],
        "derivationRule": "exp(mean(ln(post-vaccination titer / pre-vaccination titer)))",
        "baselineDefinition": "Sera collected before study vaccination (Visit 1)",
        "baselineVisit": "Visit 1",
        "analysisWindow": "Visit 2 (20vPnC and 13vPnC matched) or Visit 3 (13vPnC/PPSV23 7 additional)",
        "imputationRule": "Limited to subjects with nonmissing values both before and after vaccination.",
        "unit": "Ratio"
      },
      {
        "id": "dv_4",
        "name": "Proportion of subjects with OPA titers ≥LLOQ",
        "variableType": "Categorical",
        "sourceVariables": [
          "OPA titers",
          "LLOQ"
        ],
        "derivationRule": "(Count of subjects with titer >= LLOQ / Total subjects) * 100",
        "baselineDefinition": "Sera collected before study vaccination (Visit 1)",
        "baselineVisit": "Visit 1",
        "analysisWindow": "Visit 1, Visit 2, and Visit 3 as applicable",
        "imputationRule": "Missing assay results will not be replaced or imputed.",
        "unit": "%"
      },
      {
        "id": "dv_5",
        "name": "Proportion of subjects with ≥4-fold rise in OPA titer",
        "variableType": "Categorical",
        "sourceVariables": [
          "OPA titers"
        ],
        "derivationRule": "(Count of subjects with (Post-vaccination titer / Visit 1 titer) >= 4 / Total subjects) * 100",
        "baselineDefinition": "Sera collected before study vaccination (Visit 1)",
        "baselineVisit": "Visit 1",
        "analysisWindow": "Visit 2 (20vPnC and 13vPnC matched) or Visit 3 (13vPnC/PPSV23 7 additional)",
        "imputationRule": "Missing assay results will not be replaced or imputed.",
        "unit": "%"
      },
      {
        "id": "dv_6",
        "name": "OPA GMR (Younger Cohorts to Older Cohort)",
        "variableType": "Custom",
        "sourceVariables": [
          "OPA titers"
        ],
        "derivationRule": "exp(mean(ln(Cohort 2 or 3)) - mean(ln(Cohort 1)))",
        "baselineDefinition": "N/A",
        "baselineVisit": "N/A",
        "analysisWindow": "Visit 2 (1 month after vaccination)",
        "imputationRule": "Missing assay results will not be replaced or imputed.",
        "unit": "Ratio"
      }
    ],
    "stateMachine": {
      "id": "sm_1",
      "initialState": "Screening",
      "terminalStates": [
        "Early Termination",
        "Completed"
      ],
      "states": [
        "Screening",
        "Vaccination 1",
        "Vaccination 2 Or Follow Up",
        "Immunogenicity Follow Up",
        "End Of Study Telephone Contact",
        "Early Termination"
      ],
      "transitions": [
        {
          "fromState": "Screening",
          "toState": "Vaccination 1",
          "trigger": "Progress to Vaccination 1"
        },
        {
          "fromState": "Vaccination 1",
          "toState": "Vaccination 2 Or Follow Up",
          "trigger": "Progress to Vaccination 2 Or Follow Up"
        },
        {
          "fromState": "Vaccination 2 Or Follow Up",
          "toState": "Immunogenicity Follow Up",
          "trigger": "Progress to Immunogenicity Follow Up"
        },
        {
          "fromState": "Immunogenicity Follow Up",
          "toState": "End Of Study Telephone Contact",
          "trigger": "Progress to End Of Study Telephone Contact"
        }
      ],
      "epochIds": {
        "Screening": "SCREENING",
        "Vaccination 1": "VACCINATION_1",
        "Vaccination 2 Or Follow Up": "VACCINATION_2_OR_FOLLOW_UP",
        "Immunogenicity Follow Up": "IMMUNOGENICITY_FOLLOW_UP",
        "End Of Study Telephone Contact": "END_OF_STUDY_TELEPHONE_CONTACT",
        "Early Termination": "EARLY_TERMINATION"
      }
    },
    "dosingRegimens": [
      {
        "id": "dosing_llm_1",
        "treatmentName": "20-valent Pneumococcal Conjugate Vaccine (20vPnC) / PF-06482077",
        "frequency": "Single",
        "route": "IM",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 0.0,
            "unit": "dose",
            "description": "Single injection"
          }
        ],
        "durationDescription": "1 day"
      },
      {
        "id": "dosing_llm_2",
        "treatmentName": "Comparator / Placebo",
        "frequency": "Single",
        "route": "IM",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 0.0,
            "unit": "dose",
            "description": "Matching active vaccine"
          }
        ],
        "durationDescription": "1 day"
      }
    ],
    "visitWindows": [
      {
        "id": "visit_10",
        "visitName": "screening",
        "targetDay": -14,
        "windowBefore": 7,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 1,
        "sourceText": "or sponsor include, but are not limited to, failure to meet entrance criteria (screening failure), AE, death, pregnancy, protocol deviation, lost to follow-up, no longer willing to participate in the "
      },
      {
        "id": "visit_3",
        "visitName": "Visit 2",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 2,
        "sourceText": "6.1.2. Cohort 1: Visit 2 (Vaccination 2 – 28 to 42 Days After Visit 1)................41 6.1.3. Cohort 1: Visit 3 (Follow-up – 28 to 42 Days After Vaccination 2)..........42"
      },
      {
        "id": "visit_4",
        "visitName": "Visit 3",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 3,
        "sourceText": "6.1.3. Cohort 1: Visit 3 (Follow-up – 28 to 42 Days After Vaccination 2)..........42"
      },
      {
        "id": "visit_6",
        "visitName": "Visit 4",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 4,
        "sourceText": "6.1.4. Cohort 1: Visit 4 (6-Month Safety Collection [Telephone Contact] – 168 to 196 Days After Vaccination 1).............................................................42 6.2. Cohorts 2 and 3 ....."
      },
      {
        "id": "visit_7",
        "visitName": "Early Termination",
        "targetDay": null,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 5,
        "sourceText": "6.1.4. Cohort 1: Visit 4 (6-Month Safety Collection [Telephone Contact] – 168 to 196 Days After Vaccination 1).............................................................42 6.2. Cohorts 2 and 3 ....."
      },
      {
        "id": "visit_8",
        "visitName": "Visit 23",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 6,
        "sourceText": "Subjects in Cohort 1 who received 13vPnC at Vaccination 1 will receive PPSV23 at Vaccination 2. Approximately 2000 subjects 60 through 64 years of age and 1000 subjects 65 years of age and older will "
      },
      {
        "id": "visit_11",
        "visitName": "baseline",
        "targetDay": 0,
        "windowBefore": 1,
        "windowAfter": 1,
        "isRequired": true,
        "visitNumber": 7,
        "sourceText": "establish a clinical baseline. Significant medical history, significant findings from any physical examination, if performed, and temperature measurements will be documented and recorded in the source"
      },
      {
        "id": "visit_llm_None",
        "visitName": "Unscheduled Visits",
        "targetDay": null,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": false,
        "visitNumber": 8,
        "epoch": "All Cohorts"
      },
      {
        "id": "visit_9",
        "visitName": "randomization",
        "targetDay": 1,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 9,
        "epoch": "Cohort 1",
        "sourceText": "Assign randomization number  Obtain blood sample for immunogenicity (~50 mL)c"
      },
      {
        "id": "visit_12",
        "visitName": "Day 7",
        "targetDay": 7,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 10,
        "sourceText": "each day will be recorded in the e-diary. In the event of a fever on Day 7, temperature will be collected daily until fever has resolved (1 day of temperature <100.4F [<38.0C]) in order to collect a"
      },
      {
        "id": "visit_llm_2",
        "visitName": "Cohort 1: Visit 2 (Vaccination 2)",
        "targetDay": 35,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 2,
        "targetWeek": 5,
        "epoch": "Cohort 1"
      },
      {
        "id": "visit_llm_3",
        "visitName": "Cohort 1: Visit 3 (Follow-up)",
        "targetDay": 70,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 3,
        "targetWeek": 10,
        "epoch": "Cohort 1"
      },
      {
        "id": "visit_llm_4",
        "visitName": "Cohort 1: Visit 4 (6-Month Safety Collection [Telephone Contact])",
        "targetDay": 182,
        "windowBefore": 14,
        "windowAfter": 14,
        "isRequired": true,
        "visitNumber": 4,
        "targetWeek": 26,
        "epoch": "Cohort 1"
      },
      {
        "id": "visit_5",
        "visitName": "Follow-up",
        "targetDay": 365,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 14,
        "sourceText": "6.1.3. Cohort 1: Visit 3 (Follow-up – 28 to 42 Days After Vaccination 2)..........42"
      }
    ],
    "randomizationScheme": {
      "id": "randomization_1",
      "ratio": "Cohort 1: 1:1; Cohort 2: 3:1; Cohort 3: 3:1",
      "method": "Randomized, double-blind",
      "centralRandomization": true,
      "blockSize": "Not specified",
      "stratificationFactors": [
        {
          "id": "strat_1",
          "name": "Age",
          "categories": [
            "<49 years",
            "≥49 years"
          ],
          "isBlocking": false,
          "sourceText": "age"
        },
        {
          "id": "strat_llm_1",
          "name": "Age (Cohort 1)",
          "categories": [
            "60 through 64 years of age",
            "65 years of age and older"
          ],
          "isBlocking": false
        },
        {
          "id": "strat_llm_2",
          "name": "Cohort Assignment (Age-based)",
          "categories": [
            "Cohort 1: ≥60 years",
            "Cohort 2: 50 through 59 years",
            "Cohort 3: 18 through 49 years"
          ],
          "isBlocking": false
        }
      ],
      "sourceText": "20-valent Pneumococcal Conjugate Vaccine (20vPnC)\nB7471007\nFinal Protocol Amendment 2, 11 February 2019\nPFIZER CONFIDENTIAL\nPage 12\nPfizer is developing a new 20-valent pneumococcal conjugate vaccine "
    }
  }
}